Literature DB >> 22473128

Lessons learned from the 2007 to 2009 Haemophilus influenzae type B vaccine shortage: implications for future vaccine shortages and public health preparedness.

Allison T Chamberlain1, Katelyn Wells, Katherine Seib, Amanda Kudis, Claire Hannan, Walter A Orenstein, Ellen A S Whitney, Alan R Hinman, James W Buehler, Saad B Omer, Ruth L Berkelman.   

Abstract

OBJECTIVE: To understand immunization programs' experience managing the 2007 to 2009 Haemophilus influenzae type B (Hib) vaccine shortage and identify ways in which the US immunization system can be improved to assist in responses to future shortages of routine vaccines and large-scale public health emergencies.
METHODS: An Internet-based survey was conducted from July 2009 to October 2009 among the 64 city, state, and territorial immunization program managers (IPMs).
RESULTS: Fifty-eight percent (37 of the 64) of IPMs responded. Forty percent of responding IPMs indicated not having enough Hib vaccine within their Vaccines for Children program to fulfill the temporary 3-dose recommendation issued in December 2007 in response to the Hib vaccine shortage. While 73% of IPMs indicated success in monitoring provider inventory and 68% indicated success in monitoring doses administered during the shortage, fewer than half indicated success in monitoring providers' compliance with shortage-specific recommendations regarding Hib vaccine. Forty-six percent of IPMs used their immunization information system (IIS) to monitor provider compliance with recommendations regarding Hib vaccine use, and of these, nearly 60% reported success in monitoring provider compliance with recommendations compared with 35% of IPMs who did not use their IIS in this way. Forty-two percent of IPMs felt that the Centers for Disease Control and Prevention (CDC) was successful in determining stockpiled vaccine allocations to their program, and 56% felt that the CDC was successful in communicating its rationale for their immunization program's Hib allocation during the shortage.
CONCLUSIONS: Experiences from the 2007 to 2009 Hib vaccine shortage offer insights on how the US immunization system and system-wide response to vaccine shortages can be improved. Results from this survey suggest that improving vaccine transfer between jurisdictions and using IIS to track provider compliance with shortage recommendations are 2 ways that can help the US immunization system respond to future vaccine shortages and large-scale public health emergencies like influenza pandemics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473128     DOI: 10.1097/PHH.0b013e31821dce27

Source DB:  PubMed          Journal:  J Public Health Manag Pract        ISSN: 1078-4659


  4 in total

1.  Challenges and changes: immunization program managers share perspectives in a 2012 national survey about the US immunization system since the H1N1 pandemic response.

Authors:  Katherine Seib; Allison Chamberlain; Katelyn Wells; Eileen Curran; Ellen As Whitney; Walter A Orenstein; Alan R Hinman; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Changes in immunization program managers' perceptions of programs' functional capabilities during and after vaccine shortages and pH1N1.

Authors:  Leah F Moriarty; Saad B Omer; Katherine Seib; Allison Chamberlain; Katelyn Wells; Ellen Whitney; Ruth Berkelman; Robert A Bednarczyk
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

3.  Vaccine providers' perspectives on impact, challenges, and response during the California 2010 pertussis outbreak.

Authors:  Jessica L Silvaggio; Joshua Van Otterloo; Eileen A Curran; Ellen A S Whitney; Paul S Weiss; Katherine Seib; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2013-09-18       Impact factor: 3.452

4.  Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening.

Authors:  Marco Weisshaar; Robert Cox; Zachary Morehouse; Shiva Kumar Kyasa; Dan Yan; Phil Oberacker; Shuli Mao; Jennifer E Golden; Anice C Lowen; Michael G Natchus; Richard K Plemper
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.